Naxitamab and Granulocyte–Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Here, CSF2 is linked to neuroblastoma.